Purple Biotech Ltd.

Regulatory Filings • Jun 17, 2025

6K: Purple Biotech Announces Initiation of Phase 2 Study of NT219 in Patients with Head and Neck Cancer false

���� ����� ��"�	2 380
PURPLE BIOTECH LTD
Corporation no: 520031238	12724
- - -

	Israel Securities Authority			Tel Aviv Stock Exchange		C002 ( Public )		Reported via MAGNA:	17/06/2025
	www.isa.gov.il			www.tase.co.il				Reference:	2025-02-043162	Time of broadcast: 15:01 15:01

---

Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

	The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report on6K: Purple Biotech Announces Initiation of Phase 2 Study of NT219 in Patients with Head and Neck Cancer

ea024591302-6k_purpleEDGAR2_Bannerless_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
- - -
Stock Exchange/Market: NASDAQ CM	Date of revision of form structure: 06/08/2024
Address: Oppenheimer, Science Park 4 , Rehovot 7670104   , Israel Tel: 03-9333121 , 03-9311321 Fax: 03-5097196
E-mail address: ir@purple-biotech.com   Company site: www.kitovpharma.com
Previous names of reporting entity: KITOV PHARMA LTD, KITOV PHARMACEUTICALS HOLDINGS LTD, MAINROM LINE LOGISTICS LTD, ORLINE DEVELOPMENT AND INVESTMENT LTD, KADURY & HAI (MOLET) ASSETS & INVESTMENTS LTD,
Name of the Signatory: Masas Ludmer Adi Position of Signatory in the reporting corporation: Company Controller Name of Employer Company:
Address: Menachem Begin Drive 132 , Tel Aviv 6701101 Telephone: 03-9333121 Facsimile: 03-5097196 E-mail: adim@kitovpharma.com 1
Israel